CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 61 filers reported holding CABALETTA BIO INC in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $711,155 | +19.8% | 46,725 | +1.6% | 0.00% | +100.0% |
| Q2 2023 | $593,744 | -15.2% | 45,991 | -45.7% | 0.00% | -50.0% |
| Q1 2023 | $700,237 | +429.4% | 84,672 | +492.1% | 0.00% | – |
| Q4 2022 | $132,275 | +429.1% | 14,300 | -62.4% | 0.00% | – |
| Q3 2022 | $25,000 | -75.5% | 38,058 | -60.4% | 0.00% | – |
| Q2 2022 | $102,000 | -66.4% | 96,210 | -35.8% | 0.00% | -100.0% |
| Q1 2022 | $304,000 | +16.9% | 149,929 | +118.7% | 0.00% | 0.0% |
| Q4 2021 | $260,000 | -73.1% | 68,567 | -13.6% | 0.00% | -50.0% |
| Q3 2021 | $965,000 | +785.3% | 79,330 | +524.3% | 0.00% | – |
| Q2 2021 | $109,000 | -70.9% | 12,708 | -62.4% | 0.00% | -100.0% |
| Q1 2021 | $375,000 | +80.3% | 33,801 | +102.8% | 0.00% | 0.0% |
| Q4 2020 | $208,000 | +60.0% | 16,665 | +38.7% | 0.00% | – |
| Q3 2020 | $130,000 | -16.1% | 12,014 | -13.4% | 0.00% | -100.0% |
| Q2 2020 | $155,000 | – | 13,877 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |